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REVIEW
Consumption of β-glucans to spice up T cell treatment of tumors: a review
Priscilla de Graaffa,b, Coen Goversb, Harry J. Wichersb and Reno Debetsa
aLaboratory of Tumor Immunology, Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands; bFood and
Biobased Research, Wageningen University and Research, Wageningen, The Netherlands
ABSTRACT
Introduction: Adoptive T-cell treatments of solid cancers have evolved into a robust therapy with
objective response rates surpassing those of standardized treatments. Unfortunately, only a limited
fraction of patients shows durable responses, which is considered to be due to a T cell-suppressive
tumor microenvironment (TME). Here we argue that naturally occurring β-glucans can enable reversion
of such T cell suppression by engaging innate immune cells and enhancing numbers and function of
lymphocyte effectors.
Areas covered: This review summarizes timely reports with respect to absorption, trafficking and
immune stimulatory effects of β-glucans, particularly in relation to innate immune cells. Furthermore,
we list effects toward well-being and immune functions in healthy subjects as well as cancer patients
treated with orally administered β-glucans, extended with effects of β-glucan treatments in mouse
cancer models.
Expert opinion: Beta-glucans, when present in food and following uptake in the proximal gut,
stimulate immune cells present in gut-associated lymphoid tissue and initiate highly conserved pro-
inflammatory pathways. When tested in mouse cancer models, β-glucans result in better control of
tumor growth and shift the TME toward a T cell-sensitive environment. Along these lines, we advocate
that intake of β-glucans provides an accessible and immune-potentiating adjuvant when combined
with adoptive T-cell treatments of cancer.
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1. Adoptive T cell therapy: a short introduction
Adoptive T cell therapy (AT) is a well-tested and promising
approach to treat cancer and relies on the infusion of auto-
logous tumor-specific T cells [1]. Besides the use of non-mod-
ified T cells, such as tumor-infiltrating lymphocytes (TILs) or
peripheral T cell clones, one can also use T cells that are gene-
engineered to express chimeric antigen receptors (CARs) or T
cell receptors (TCRs). These CAR and TCR-engineered T cells
recognize a chosen tumor antigen, and are redirected to
selectively destroy cells expressing this antigen. While the
use of CARs has shown impressive results in B cell leukemia’s
with response rates up to 94% (reviewed in [2]), which culmi-
nated in the recent FDA approval of Kymriah [3] and Yescarta
[4], their current use in the treatment of solid tumors is lag-
ging behind these successes in hematological tumors. TCR-
engineered T cells have demonstrated clinical benefit in
patients with multiple myeloma, metastatic melanoma and
metastatic synovial sarcoma with response rates varying
between 55% and 80% (reviewed in [5]). Notwithstanding
these clinical results, particularly when treating solid tumors,
AT is generally marked by a large fraction of patients with no
or nondurable clinical responses. This suboptimal success
coincides with limited accumulation and activation of T cells
within tumors and poor persistence of these cells in the
periphery [6,7]. To keep the positive momentum of AT and
increase the durability of responses, local immune suppressive
mechanisms need to be antagonized to ensure sufficient
numbers and function of therapeutic T cells at the tumor site.
1.1. Tumor microenvironment and suppressive innate
immune cells
The tumor microenvironment (TME) provides the tumor’s archi-
tecture and nourishment, and consists of fibroblasts, endothelial
cells and immune cells, and their products such as extracellular
matrix components (EMC), cytokines and other mediators. There
are several distinct immune cell types that actively contribute to
an immunosuppressive TME, including (but not limited to) mye-
loid-derived suppressor cells (MDSCs), tumor-associated macro-
phages (TAMs), tumor associated neutrophils (TANs), immature
dendritic cells (imDCs) and regulatory T cells (Tregs). The TME
counteracts the tumoricidal function of activated immune effec-
tor cells, such as CD8 T cells and Natural Killer (NK) cells, through
various mechanisms, which are described in some detail below
with emphasis on monocytic and granulocytic cell types that
have been reported to be most responsive to β-glucans (see
Section 2).
● MDSCs: these cells constitute a heterogeneous population of
immature myeloid cells that arise from the bonemarrow [8].
The expression of indoleamine 2,3-dioxygenase (IDO) by
tumor cells is associated with MDSC infiltration [9]. MDSCs
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are generally divided into two major subsets: polymorpho-
nuclearMDSC (PMN-MDSC) andmonocyticMDSC (M-MDSC)
that are morphologically and phenotypically similar to neu-
trophils and monocytes, respectively. Within the TME,
M-MDSCs are the most prominent subset of MDSCs and
can differentiate into TAMs (see below) [8]. MDSCs have the
ability to disrupt mechanisms of immune control, such as
antigen presentation by dendritic cells (DCs), natural killer
(NK) cell cytotoxicity, and T cell activation [10].
For example, MDSCs have been reported to negatively
regulate T cell responses by the production of galectin 9,
a ligand for T cell immunoglobulin mucin-3 (Tim-3), the
latter being an immune checkpoint that upon activation
diminishes CD8 T cell responses [11]. Other examples by
which MDSCs hamper T cell proliferation and effector func-
tions include production of arginase-1, IDO and inducible
nitric oxide synthase 2 (iNOS2) [12,13]. In particular, argi-
nase-1 and IDO activity deplete local arginine and trypto-
phan, which promotes Treg development thereby blocking
cytotoxic T cell function [11]. Interestingly, the frequency of
MDSCs is correlated with disease progression in patients
suffering from melanoma [14], non-small lung cancer
(NSCLC) [15], breast cancer [16] and colorectal carcinoma
[17], and was demonstrated to be inversely correlated with
the presence of functional antigen-specific T cells in
patients with advanced melanoma [18].
● TAMs: these cells constitute a population of myeloid cells
that arise from tissue-resident macrophages of either
embryonic or monocytic origin following their recruitment
into the tumor tissue [19]. Tissue-resident macrophages or
peripheral monocytes are recruited through colony-stimu-
lating factor 1 (CSF-1), vascular endothelial growth factor
(VEGF) and chemokines such as CCL2 and CCL5 produced
by tumor and stromal cells [8,20]. TAMs represent a
dominant myeloid cell population in many solid tumors
and can display characteristics of both tumor-suppressive
M1 as well as tumor-promoting M2 macrophages [21]. M1-
like TAMs are induced by the T helper 1 (Th1)-type cytokine
IFN-γ and the production of IL-12 and IL-23 by M1-like
TAMs promotes or amplifies polarization of T cell toward
a T helper 1 (Th1) phenotype [22]. However, tumors usually
harbor TAMs with a M2-like phenotype, which can be
locally induced by T helper 2 (Th2)-type cytokines, such as
IL-4, IL-13 and IL-10 [23]. TAMs regulate tumor angiogen-
esis, metastasis, and immune suppression via different
mechanisms. For example, TAMs acquire amore pro-angio-
genic phenotype as a result from hypoxia, and become
responsive toward cytokines, such as IL-10 and transform-
ing growth factor (TGF-β), glucorticoids and immunoglo-
bulin complexes [24]. Finally, M2-like TAMs suppress anti-
tumor T cell responses through increased expression of
programmed death-ligand 1 (PD-L1) and enhanced pro-
duction of TGF-β and prostaglandin E2 (PGE2)[20]. In fact,
TAMs take part in the progression of, for example, epithelial
ovarian cancer with the frequency of TAMs being highest in
high grade compared to low grade cancer tissues [25].
Moreover, the infiltration of TAMs has been shown to
negatively associate with prognostic outcomes in several
types of tumor such as lymphoma [26].
● TANs: these cells constitute a population of granulocytic
cells that arise from peripheral neutrophils and PMN-MDSC
[27]. Neutrophils are recruited to the tumor site via locally
produced molecules such as CXCL8, CXCL5, CXCL6, and
hydrogen peroxide. Two distinct subpopulations of TANs
are described, either having immune suppressive (N2) or
immune stimulatory (N1) functions [28], with type I inter-
ferons (IFNs) representing important inducers of N1 TANs
and TGF-β of N2 TANs [29]. TANswith anN1-like phenotype
show increased tumor cytotoxicity, expression of intercel-
lular adhesion molecule 1 (ICAM1) and tumor necrosis
factor alpha (TNF-α) [29], whereas TANs with an N2-like
phenotype promote angiogenesis through the secretion
of matrix metallopeptidase 9 (MMP-9), oncostatin M,
CXCL8 and BV8/prokineticin-2 [30]. Interestingly, TANs
can acquire antigen presenting cell (APC)-like functions
and can stimulate intratumoral effector T cells, yet TANs
were demonstrated to lose APC-like properties in later
stages of tumor progression in patients with NSCLC. TANs
are able to suppress T cell function via release of arginase-1
and iNOS (reviewed in [31]). In addition, infiltrated TANs
were investigated in gastric cancer patients and were
found to express high levels of PD-L1, whichwas associated
with disease progression. This PD-L1 expression was
induced by tumor-derived granulocyte-macrophage col-
ony-stimulating factor (GM-CSF) and actively contributed
to T cell suppression [32].
1.2. Reversing immune suppressive innate immune
cells
As already outlined above, IFNs as well as pro-inflammatory
cytokines can counteract suppressive innate immune cells,
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● Orally ingested β-glucans are taken up in the proximal gut via
intestinal epithelial cells or M-cells in Peyer’s patches, following
which they are captured by subsets of CD103+ DCs and CXCR3+
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and are considered critical to obtain effective anti-tumor T
cell responses. Interferons (IFNs) represent a large group of
cytokines, typically divided among type I (generally IFN-α,β)
II (IFN-γ) and III (IFN-λ) [33]. Pro-inflammatory cytokines,
excreted from inflammation-promoting immune cells, such
as macrophages and helper T cells, include interleukins-1
(IL-1), 6, 8, 12, 18, 21, GM-CSF, and TNF-α. Production of
type I IFNs and pro-inflammatory cytokines generally occurs
downstream of pattern recognition receptors (PRRs) follow-
ing their ligation by pathogen or danger-associated mole-
cular patterns (PAMPs or DAMPs). Type I IFNs inhibit the
activity of MDSCs, resulting in the conversion of TAMs
toward a more M1-like phenotype and promote activation,
cross-presentation, and secretion of co-stimulatory mole-
cules by DCs [34]. Also, type I IFNs can reverse N2-like
TANs to those with enhanced production of TNF-α and
anti-tumor activity [35]. It is noteworthy that during early
stages of tumor development, a subset of DCs, expressing
the basic leucine zipper transcription factor ATF-like 3
(Batf3) and the surface markers CD103 and CD8α, secrete
IFN-β upon encounter with tumor cells [36]. This DC subset
is specialized in priming and cross-presentation of antigens
to CD8+ T cells, often contributing to a highly effective anti-
tumor response [37]. In fact, the absence of gene signatures
including type I IFNs and chemokines is associated with loss
of accumulation and activation of intratumoral CD8+ T cells
[38]. Anti-inflammatory cytokines such as TGF-β and IL-10,
often produced by tumor cells and tumor-infiltrating
immune cells, are involved in the impairment of DCs and
suppression of effector T cells. Delivery of pro-inflammatory
cytokines can shift the phenotypes of suppressive cell popu-
lations within the tumor. For example, IL-21 effectively con-
verses TAMs into a more M1-like phenotype [39], which
renders tumor cells more susceptible for AT. Also, adminis-
tration of high doses of IL-12 leads to enhanced anti-tumor
activity of NK cells in a B16 murine melanoma model [40].
Moreover, IL-12 was found to alter MDSCs and reprogram
them to immune-stimulating myeloid cells [41]. Lastly, N2-
like TANs were shown to re-express CCL3 and TNF-α follow-
ing their inhibition, which led to enhanced attraction of
innate (monocytes and granulocytes) as well as effector
immune cells to the tumor site [29].
2. β-Glucans stimulate innate immune cells
Dietary fibers have been widely studied for their favorable
effects on general health and well-being. Most studies have
focused on non-starch poly- and oligosaccharides [42,43] and
demonstrated beneficial effects in a diversity of diseases, such
as Alzheimer, diabetes, inflammatory bowel disease, and car-
diovascular disease [44–46]. Non-starch polysaccharides, parti-
cularly β-glucans have been demonstrated to become directly
exposed to and potentiate innate immune cells in the small
intestine through direct exposure to cells [47] or, alternatively,
reduce unwanted colonic inflammation following microbiota-
mediated fermentation into short-chain fatty acid [48,49].
These fatty acids could function as bioactive compounds and
exert a beneficial action on specific intestinal bacteria linked to
anti-inflammatory effects. Such immune effects may precede
effects on general health (discussed in more detail in Section
3). Notably, humans have always encountered β-glucans either
as part of their diet or as pathogens since β-glucans are cell
wall components that are abundantly found in plants, yeast,
fungi, and bacteria. These bioactive β-glucans consist of
D-glucose monomers linked through β-glycosidic bonds with
a β-(1→3) configuration and β-(1→6) or β- (1→4) linkages [50].
In Table 1, we have listed β-glucans that are most commonly
used in studies of immune modulation, and in Figure 1 we
have schematically exemplified the structural characteristics
and variation in branching, which are considered critical
toward the biological activities of β-glucans.
Immune modulation mediated by β-glucans requires: (1)
intestinal uptake; (2) trafficking through the body; and (3) activa-
tion of immune cells at distant lymphoid organs. These different
steps and necessary cellular interactions are shown in Figure 2.
Below we have described these individual steps in more detail.
2.1. β-Glucan sampling from the gut and its bio-
distribution to lymphoid organs
Orally administered β-glucans arrive in an undigested form in the
intestine as humans lack hydrolyzing enzymes. In the intestine,
β-glucans are likely captured by intestinal epithelial cells (IECs),
mucosal M cells, and/or subsets of CXCR3+ macrophages or
CD103+ DCs (reviewed by Batbayer and colleagues [51]). To
Table 1. Source and chemical properties of most commonly reported β-glucans.a
β-glucan Organism/species Glycosidic linkages Mw (kDa) Solubility in water Refs.
Algae Laminarin Laminaria digitata β-(1➝3, 1➝6) 3.5–7.7 Yes [114,115]
Bacteria Curdlan Alcaligenes faecali β-(1➝3) 53–2000 No [116]
Fungi Maitake Grifola frondosa β-(1➝3, 1➝6) 1000 Yes [117]
Lentinan Lentinula edodes β-(1➝3, 1➝6) 400–1000 Yes (slightly) [118]
Pachyman Poria cocos β-(1➝3, 1➝6) N.D. No
PGG Saccharomyces cerevisiae β-(1➝3, 1➝6) 120–205 Yes [76]
Pleuran Pleurotus ostreatus β-(1➝3, 1➝6) N.D. No
PSK Trametes versicolor β-(1➝3, 1➝4) 94–100 Yes [119]
Schizophyllan Schizophyllum commune β-(1➝3, 1➝6) 450 Yes [120]
Scleroglucan Sclerotium rolfsii β-(1➝3, 1➝6) 1000 Yes [114]
SSG Sclerotinia sclerotiorum β-(1 ➝ 3) N.D. Yes
WGP Saccharomyces cerevisiae β-(1➝3, 1➝6) N.D. No
Yeast Saccharomyces cerevisiae β-(1➝3, 1➝6) 35–5000 No [121]
Zymosan Saccharomyces cerevisiae β-(1➝3, 1➝6) N.D. No
Higher plants Barley Hordeum vulgare β-(1➝3, 1➝4) 23–137 Yes (slightly) [116]
Oat Avena sativa β-(1➝3, 1➝4) 40–359 Yes [122]
aN.D.: Not determined; PGG: poly-glucopyranosyl-glucopyranose; PSK: polysaccharide-K; SSG: sclerotinan; WGP: whole glucan particles.
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elucidate the exact route of uptake, Rice and colleagues fluores-
cently labelled and orally administered soluble β-glucans (scler-
oglucan, glucan phosphate and laminarin) to mice [52]. This
study demonstrated that the first step in β-glucan uptake is its
internalization by IECs and/or M cells in Peyer’s patches. Uptake
by IECs appeared to be independent of dectin-1 (a PRR that binds
β-glucans, see below), whereas uptake by gut-associated lym-
phoid tissue (GALT) resulted in increased expression of dectin-1
as well as toll-like receptor 2 (TLR2), suggesting that these two
receptors contribute to the uptake of β-glucans by M cells.
Interestingly, uptake of β-glucans was accompanied by an
increase in systemic IL-6 and IL-12 levels, but not IL-2, IFN-γ, or
TNF-α [52]. In extension to this finding, there are multiple reports
pointing out that β-glucans result in up-regulated expression of
pro-inflammatory cytokines and other mediators, most likely
derived from macrophages and DCs (see Table 2).
Figure 1. Glucans and their chemical structures. Examples and configurations of β-glucans derived from bacteria, fungi, yeast and cereal.
Figure 2. Uptake, trafficking and immune activation of β-glucans. Beta-glucans enter the proximal small intestine, via intestinal epithelial cells or M cells in Peyer’s
patches, cohere they are captured by CXCR3 macrophages or CD103 DCs. Exposure to β-glucans induces these cells to migrate via the bloodstream to the bone
marrow or via the lymph system to mesenteric or more distant lymph nodes. (a) Beta-glucans bind to innate immune cells via PPRs generally resulting in signaling
through conserved pathways, and yielding cellular activation. (b) Within bone marrow, degradation products of large β-glucans bind to CR3 on neutrophils resulting
in their activation. (c) Within lymphoid organs, DCs and macrophages produce a variety of type-I IFNs and pro-inflammatory cytokines, ultimately culminating in
enhanced differentiation of effector lymphocytes. Abbreviations: AP-1: Activator protein 1; CR3: Complement receptor 3; CXCR3: CXC chemokine receptor 3; DC:
Dendritic cell; IFN-I: Type I interferons; IFN-γ: Interferon gamma; IL: Interleukin; LacCer: Lactosylceramide; MØ: Macrophage; NFAT: Nuclear factor of activated T-cells;
NF-kB: Nuclear Factor Kappa Bèta; TNF-α: Tumor necrosis factor alpha; TLR: Toll-like receptor.
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In another study of β-glucan uptake, Hong and colleagues
orally administered fluorescently labelled barley and yeast
whole glucan particles (WGP) to mice [47]. In this study, β-
glucan particles were detected 3 days after intake in splenic
and lymph node macrophages, and 4 days after intake in bone
marrow macrophages, which suggests migration of intestinal
immune cells following exposure to β-glucans. Once captured,
macrophages can breakdown β-glucans and secrete soluble
fractions of β-glucans that bind and prime complement recep-
tor 3 (CR3) present on macrophages and granulocytes.
Fragmented and/or soluble β-glucans, however, might not
unequivocally bind nor stimulate the same receptors as full
length β-glucans. In fact, small β-glucan particles with a back-
bone length below seven glucose units cannot bind to dectin-
1 [53], and soluble β-glucans cannot initiate clustering of
dectin-1 in immunological synapses, and consequently cannot
activate this receptor [54]. Another study employing oral
administration of soluble β-glucans demonstrated the pre-
sence of significant serum levels of β-glucans after 14 days
of administration, albeit a small fraction of the total amount of
administered β-glucan [55]. This, in addition to the intestinal
uptake and migration via innate immune cells, constitutes
another route of β-glucan trafficking throughout the body in
addition to the intestinal uptake and migration in β-glucan-
activated innate immune cells. Collectively, the above studies
argue that β-glucans, once having passed the intestinal
epithelium, reach distant lymphoid organs via blood or
lymph via two non-mutually exclusive routes either making
use of subsets of innate immune cells or cell-free transport.
2.2. β-Glucan receptors
When β-glucans reach distant lymphoid structures, or solid
tumors for that matter, they activate innate immune cells via
ligation of β-glucan-specific PRRs. PPRs consist of two classes
of intracellular receptors: RIG-I-like receptors and NOD-like
receptors; as well as two classes of plasma membrane recep-
tors: TLRs and C-type lectin-like receptors. Dectin-1 is one of
the best characterized PRRs with respect to β-glucan binding
which belongs to the class of C-type lectin-like receptors and
is reported to bind to zymosan, scleroglucan, schizophyllan,
lentinan, curdlan and WGP [53,54,56–59]. Dectin-1 is found on
the surfaces of monocytes, macrophages, neutrophils, DCs,
and T cells [60]. Studies using synthetic β-glucans revealed
that binding to dectin-1 requires a configuration only consist-
ing of β-(1→3) as β-glucans derived from barley with a mixed
configuration consisting of β-(1→3, 1→4) are not recognized by
dectin-1 [61]. Besides dectin-1 several other PPRs were
demonstrated to bind β-glucans. In example, lactosylceramide
receptor (LacCer), scavenger receptor, mannose receptor and
CR3 were reported to bind extracts from Pneumocystis carinii,
glucan phosphate, baker’s yeast β-glucan, laminarin and
zymosan [62–65]. Several studies reported collaborative sig-
nalling of dectin-1 in combination with TLRs [66]. In fact,
dectin-1 was suggested to collaborate with TLR2 in its binding
of curdlan and zymosan [67,68]. Expression patterns of these
PRRs are not limited to immune cells, but also include epithe-
lial cells, which suggests IECs can respond to β-glucan intake.
It is noteworthy that β-glucan receptors are not limited to the
binding of single β-glucans; and vice versa β-glucans are not
limited to single receptors, making this ligand:receptor system
highly redundant.
PRRs have evolved prior to other immune receptors and,
when ligated by β-glucans, mediate signaling through
highly conserved intracellular signaling pathways. These
pathways consist of the activation of transcription factors,
such as nuclear factor kappa-light-chain-enhancer (NF-κB) of
activated B cells and interferon regulatory factors (IRFs),
which results in production of type I IFNs and pro-inflam-
matory cytokines. For instance, a type I IFN gene signature
was promoted in human DCs that were stimulated with
WGP and curdlan [69] as well as in human and murine
Table 2. Effects of β-glucans toward immune cells.a
Immune cell typeb β-glucan Potentiation of: Attenuation of: Refs.
Neutrophils β-(1→6)-glucan (from
Candida albicans)c
PGGc
● Gene expression of heat shock proteins
● Production of ROS
● Phagocytosis
● Complement cascade and opsonization by C3b and further
degradation in iC3b and C3dg
[123,124]
Macrophages Barley, Oat, Lentinanc
Wellmune Soluble,
Lentinanc
● Gene expression of IL-1β, IL-8 and IL-10
● Gene expression of C-type lectin receptors
● Skewing macrophages toward an alternative, M1-like gene
expression profile
[125,126]
Dendritic cells WGPc
Curdlanc
● Gene expression of IL-6, IL-12, IL-2, TNF-α and IFN-γ
● Surface expression of CD11c, HLA-DR, CD86 and CD40
● Production of IFN- γ, IL-2 and IL12p40
● Gene expression and protein secretion of IL-1β, IL-6, and IL-23
[127,128]
B lymphocytes Curdlan, Zymosanc ● Production of TNF-α, IL-6 and IL-8 ● IgM production and B-cell
proliferation
[75]
Myeloid-derived
suppressor cells
Curdland ● Gene expression of IL-12p35
● Surface expression of CD11c, CD40, CD86, MHCII and CD80
● Arginase activity and
nitrites in spleen
[113]
aiC3b: inactivated C3b; IFN-γ: interferon gamma; IgM: immunoglobulin M; MHCII: major histocompatibility complex II; ROS: reactive oxygen species; TNF-α: tumor
necrosis factor alpha.
bFor immune cell types not listed (such as T lymphocytes), β-glucans were not (yet) reported to induce direct effects
cHuman primary cells and cell lines
dMouse study
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macrophage cell lines stimulated with a β-glucan derived
from A. pullulan [70]. More specifically, the intracellular
receptors NOD1 and NOD2 can interact with the inflamma-
some NLRP3, which then leads to production of IL-1 cyto-
kines [71]. Interestingly, NLRP3 was shown to be essential
for curdlan-induced IL-1β secretion in human macrophages,
which depended on both dectin-1 and spleen tyrosine
kinase (SYK) signaling [72]. Ligation of dectin-1 and CD14
also triggers activation of the transcription factor nuclear
factor of activated T-cells in macrophages and DCs
(reviewed in [73]), often upstream of the production of
pro-inflammatory cytokines. Other examples of β-glucans
binding to PRRs and initiating the activation of transcription
factors, include a β-glucan isolated from G. lucidum, which
was reported to ligate TLR4, activate NF-κB, c-Jun
N-terminal kinase (JNK) and extracellular-signal-regulated
kinase (ERK), and result in expression of co-stimulatory
receptors and production of pro-inflammatory cytokines by
DC. These β-glucan-matured DCs were proved to be effi-
cient T cell activators in an allogeneic in vitro setting [74].
Similarly, curdlan was shown to ligate dectin-1, signal
through SYK, ERK, JNK, NF-κB and activator protein 1 (AP-
1), and increase the production of TNF-α, IL-6 and IL-8, but
not immunoglobulins by B cells [75]. Also, the high mole-
cular weight β-(1→3), (1→6)-glucan from baker’s yeast (PGG)
was demonstrated to ligate the lactosylceramide receptor,
activate NF-κB, and induce an oxidative burst in human
neutrophils [76].
In extension to the above reports, other studies investi-
gated whether β-glucan could revert phenotypes of
immune suppressive innate immune cells. Along these
lines, WGP was shown to inhibit M-MDSC activity by pro-
moting the differentiation of this population into a more
mature population through dectin-1 ligation and the acti-
vation of the major transcription pathway NF-κB [77]. In
addition, zymosan and curdlan enabled conversion of
immune-suppressive TAMs into M1-like TAMs with a potent
T cell-stimulating activity ([78] and de Graaff et al., manu-
script in preparation). For neutrophils is has been
described that WGP primes these cells in a CR3-dependent
manner. Complement activation within the tumor, which
occurs when antibodies bind to tumor-associated antigens
(TAA), leads to iC3b deposition and triggers phagocyte
killing of iC3b-opsonized tumor cells by WGP-primed neu-
trophils [79].
3. Immune effects of β-glucans in healthy humans
and cancer patients
During the last decade, numbers of clinical trials have investi-
gated health benefits of β-glucans. These studies were per-
formed with healthy volunteers, athletes or elderly and, in
some cases, assessed immunological effects (see Table 3).
Notably, β-glucans have also been tested as an oral adjuvant
to cancer patients receiving standard of care therapy. These
latter studies mostly focused on β-glucans’ ability to reduce
adverse effects of standard therapies and improve quality of
life (see Table 4).
3.1. β-Glucans to improve well-being and immune
activity in healthy subjects
The effects of β-glucans derived from S. cerevisiae, L. edodus, P.
ostreatus, S. uvarum, A. sativa, Agrobacterium spp. and H. vul-
gare in healthy subjects have been tested in 15 different
clinical studies from 2006 onwards. Importantly, no toxic or
adverse effects were observed after oral administration of
different doses of these β-glucans. Despite inconsistencies
between studies regarding design, β-glucan dose (i.e. 50 mg
to 10 g/day), duration of intervention (i.e. 4 to 90 days), and
analyzed parameters, we have drawn the following general
conclusions with respect to health, immunity, and microbiota.
First, health effects have been analyzed using various read-
outs with two studies reporting on upper respiratory tract
infection (URTI) symptoms, one study on cold and flu symp-
toms, and another study on flow-mediated dilation of conduit
artery (a measure used for nitric oxide-dependent endothelial
function) [80–83]. These studies revealed a beneficial effect of
β-glucan intervention on the mentioned parameters.
Second, immune effects have particularly been investi-
gated with respect to immune effector cells, not innate
immune cells, and included both humoral as well as cellular
immunity. For example, a 6-week intervention with the β-
glucan lentinan resulted in a significant increase in B cell
numbers in blood [84]. This increase in B cell numbers
matches reported increases in IgA levels in saliva in three
other independent studies [80,85,86]. As low levels of IgA
associate with increased risk of URTI, the β-glucan-mediated
increase in IgA levels might protect against URTI [87]. As
mentioned above, one of these studies indeed correlated
the increase in IgA levels to a decreased frequency of
cold/flu symptoms [80]. Another study reported that
increased IgA levels were accompanied by reduced levels
of C-reactive protein (CRP) in serum [86]. One may speculate
that increased IgA levels might protect against and reduce
inflammatory responses, which may be mirrored by reduced
CRP levels.
In addition to effects toward humoral immunity, most clin-
ical trials reported on effects toward NK cells, CD4 and CD8 T
cells. Interestingly, two studies observed that Immunoglucan
and Agrobacterium spp. R259 resulted in increased numbers of
NK cells in blood and enhanced activity of blood-derived NK
cells [83,88]. Furthermore, another study reported that
Immunoglucan maintained NK cell activity during a recovery
period (following a 20-min intensive exercise at the end of the
supplementation period), whereas NK cell activity dropped in
the placebo group [89]. Yeast β-glucan was also able to
increase circulating fractions of monocytes after a period of
exercise [90]. Two other studies described the intake of the
‘active hexose correlated compound’ (AHCC) in a non-exercise
setting and reported increased numbers of CD11c-positive
DCs [91] and increased numbers of IFN-γ and TNF-α producing
CD4+ and CD8+ T cells in blood [92]. Notably, the latter effect
was observed until 30 days after discontinuation of β-glucan
intake.
Lastly, a study by Cosola and colleagues reported a
decrease in p-cresyl sulfate levels in urine and an increase in
short chain fatty acid levels in feces upon oral administration
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of a β-glucan derived from H. vulgare, suggesting a sacchar-
olytic shift in gut microbiota metabolism [82]. Zitvogel and
colleagues demonstrated a dominance of distinct commensal
species in patients who showed a clinical response toward PD-
1 checkpoint inhibitors, making the observed effect of β-glu-
cans on the microbiome highly relevant in the context of T cell
therapies [93].
In general, these studies reported increased frequencies,
but not activity, of various immune cell types which suggests
enhanced immune-mediated alertness toward protrusion of
homeostasis.
3.2. β-Glucans as adjuvants to anti-cancer therapy
β-glucans have been applied to cancer patients receiving
standard treatments, such as chemotherapy, radiotherapy,
monoclonal antibody or hormonal therapy. Of the 11 studies
that have been performed so far, 10 studies have properly
documented the name and origin of the β-glucan; in 6 studies
cancer patients received S. cerevisiae (yeast) and in 4 studies
patients received L. edodes (shiitake) (included in Table 4). In
general terms, the use of β-glucans demonstrated a reduction
of adverse effects of chemotherapy such as oral mucositis and
diarrhea and an improvement of quality of life [94–97]. These
effects appeared not related to a specific type of cancer or β
glucan per se as observations included patients with color-
ectal, gynecological or breast cancer who received chemother-
apy and were administered L. edodes, S. cerevisiae or A. blazei.
Numbers of studies report changes in immunological para-
meters. For instance, a study by Albeituni and colleagues
reported on administration of WGP in NSCLC patients which
resulted in decreased frequencies of MDSCs in blood (Table 4)
[98]. Oral ingestion of Lentinus edodes mycelia extract (LEM) in
patients with gastrointestinal cancer was accompanied by an
increased frequency and activity of NK cells in blood [99]. The
binding of lentinan, the β-glucan found in Lentinus edodes
and in LEM, to CD14+ monocytes appeared to correlate with
an improved quality of life as observed in patients with color-
ectal cancer [97]. Furthermore, an increase in total leukocyte
count was found in patients with prostate adenocarcinoma
who received carboxymethyl-glucan [100], and an increase in
monocyte count was observed in breast cancer patients who
received Imuneks β-glucan [101]. Besides changes in frequen-
cies of immune cells, Imuneks also resulted in decreased levels
of IL-4 and increased levels of IL-12 in serum from breast
cancer patients, measured during two courses of chemother-
apy [102].
Along these lines, it is noteworthy that a phase II clinical
trial is currently being performed in which PGG is applied as
adjuvant to Pembrolizumab, a humanized mAb against PD-1,
in patients with advanced melanoma or triple negative breast
cancer [103].
Taken together, it appears that when homeostasis becomes
protruded (only then), β-glucans are expected to support a
pro-inflammatory immune response, which according to in
vitro and in vivo studies often culminates in a Th1-type T cell
response. Although most studies focused on quality of life
rather than tumor growth, we anticipate that the observed
immune modulatory effects of β-glucans can support anti-
tumor responses.
4. Supportive effects of β-glucans toward adoptive
T cell therapy in mouse tumor models
Besides cancer patients, interventions with β-glucans have
been analyzed in more detail for their effect on tumor growth
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in various mouse models. Oral administration of different β-
glucans was tested in the following tumor models: mammary
carcinoma; B cell lymphoma; lung carcinoma; breast adeno-
carcinoma; melanoma; and colon carcinoma, and in some of
these models β-glucans were combined with chemotherapy,
vaccination, proteins or antibody treatment; listed in detail in
Table 5.
In mouse models β-glucans have been administered in
curative and preventive settings. In one study, a direct com-
parison between a curative and preventive setting has been
performed using a model of BALB/c mice with subcutaneous
inoculated CT26 colon-carcinoma cells [104]. In this model,
addition of LEM did not result in reduced growth of an already
established tumor, but addition of this extract 1 week prior to
tumor inoculation did significantly reduce tumor growth. In
most studies, β-glucan interventions delayed both the onset
of tumor growth [105] as well as the progression of already
established tumors (all studies monitored tumor growth,
except for one study that looked at cecum weight in colon
carcinoma [106], and another study that looked at melanoma
mass [107]). Notably, two studies documented in their materi-
als and methods two transplanted cell lines but only reported
the immune effects toward one of these cell line [108,109].
Various mice studies also investigated the effects of
β-glucan intake on subsets of immune cells within TME,
blood or other organs. There were 7 out of 16 studies that
reported increased IFN-γ production following ex-vivo stimula-
tion of either blood-derived T cells, splenocytes, cells from
tumor or immune tissues, following uptake of β-glucans
[106–108,110–113]. In the study where cells from GALT
showed increased IFN-γ production following ex-vivo stimula-
tion, authors argued that administered WGP β-glucans
induced IL-12 and TNF-α production by DCs and stimulated
DC migration into the tumor, which resulted in local expan-
sion of T cells [108]. In another study, mice received T cells
transgenic for an OVA-specific TCR (used as a model antigen),
and demonstrated that the simultaneous addition of WGP
resulted in an enhanced anti-tumor responses against estab-
lished Lewis Lung Carcinoma (LLC) transfected with OVA [108].
Detailed analysis revealed that administration of WGP signifi-
cantly increased the frequency of memory T cells in spleens
(Table 5). Furthermore, two tumor-bearing mice models (lung
carcinoma and breast adenocarcinoma) revealed that WGP
administration led to conversion of M-MDSC to immune-
potentiating APCs (CD11c+ DC) [98], similar as observed in
the human setting [98]. In these studies [98], APCs were
shown to cross-present antigen and to prime CD8 T cells
directed to OVA. Li and colleagues tested whether orally
administered WGP to mice with established lung carcinoma
and lymphoma would directly affect APCs [108], and observed
significantly increased numbers of tumor-infiltrating DCs and
macrophages upon WGP treatment. Moreover, expression of
the co-stimulatory molecules CD80, CD86 and MHC class II was
significantly upregulated by CD8α+ CD11c+ DCs in spleens
that had captured apoptotic tumor cells in mice treated with
WGP. These findings were linked to a stronger local expansion
of antigen-specific CD4+ and CD8+ T cells, and likewise
enhanced IFN-γ production by TILs. Despite these immunolo-
gical analyses, it remains unclear how WGP affects the
migration of DCs into the tumor tissue, and authors specu-
lated that particulate WGP may in fact mobilize DC precursors
from the bone marrow.
Ishikawa and colleagues investigated the effects of β-glu-
can on age-associated attenuation of immune competence,
which paradoxically results from age-associated inflammation.
Aged individuals demonstrated increased IL-6 and TNF-α
levels in serum and early accumulation of MDSCs into tumor
sites. The latter appeared to relate to the increased IL-6 levels
which inhibited Th1 responses and increased numbers of
MDSC. In this study an oral intervention with LEM retarded
tumor growth of CT26 colon carcinoma in aged mice, which
correlated with reduced IL-6 serum levels. Authors also
demonstrated that neutralizing serum TNFα suppressed the
induction of anti-tumor T cells, whereas neutralizing serum IL-
6 augmented the induction of these cells. Collectively, these
results suggest that LEM intervention specifically modulates
the inflammatory immune responses from an anti-tumor effect
toward a Th1-type T cell response [104].
5. Conclusion
There is an exponential growth in the number of AT studies for the
treatment of different tumors. Despite clinical successes, there is
however still a large number of patients that does not show
durable response, which has been attributed in large part to T
cell evasive mechanisms of tumors. To re-establish anti-tumor T
cell responses, it is necessary to reverse immune-suppressive
immune populations such as MDSCs, TAMs and TANs, that have
co-evolved with tumors and helped sculpting an immune tolerant
micro-environment, into more immune-potentiating APCs via
induced expression of pro-inflammatory cytokines and type I
IFNs. In this review, we argue that β-glucan fibers, acting as
PAMPS or DAMPs and found in cell walls of cereals, plants, fungi
and bacteria, activate innate immune cells, which can result in an
immunologically favorable conversion of the TME, and sensitize
tumors for enhanced T cell entry and activity. Along this hypoth-
esis we have provided a comprehensive overview of the immune
modulatory capacity of orally applied β-glucans in healthy
humans and cancer patients and have delineated how these
capacities can be exploited to support the safety and efficacy of
AT. First, β-glucans reduce chemotherapy-related adverse effects
and enhance quality of life. Second, β-glucans enhance blood
frequencies and activities of APCs, such as monocytes and neu-
trophils, as well as effector lymphocytes, such as NK cells, which is
mostly accompanied by reduced frequencies of MDSCs. In exten-
sion to these findings in humans, mice studies demonstrated that
β-glucans delay outgrowth of the tumor, which again occurs hand
in hand with effects toward APCs and enhanced numbers and
activities of NK cells and CD4+ and CD8+ T cell within tumors. It is
noteworthy that the clinical use of β-glucans is safe, can easily be
implemented at low additional costs, and would support self-
assertiveness and self-awareness amongst cancer patients.
6. Expert opinion
Development of AT during the past decades has resulted in
clinical objective response rates up to 80%, with complete
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response rates plateauing at 20%. One of the major current
challenges of this therapy is to improve the durability of anti-
tumor T cell responses. In the current contribution, we postulate
that oral administration of β-glucans represents an adjuvant
treatment to augment quantity and quality of intratumoral effec-
tor T cells, thereby supporting AT therapies.
Beta-glucans consist of polymeric D-glucose monomers
with a backbone generally consisting of β-(1→3) bonds, and
branched via β-(1→4) or β-(1→6) links. Beta-glucans are stable
compounds found in cell walls of plants and micro-organisms
that resist passage through the digestive tract. Figure 2 sum-
marizes studies, often using fluorescently labelled β-glucans,
that investigated intestinal uptake via epithelial cells and M
cells, triggering of local CXCR3+ macrophages and CD103+
DCs, and activating effector NK and T cells in more distant
lymphoid organs. Beta-glucans trigger innate immune cells via
binding to PRRs, such as dectin-1, initiate type I IFNs and pro-
inflammatory signaling cascades, and mediate the acquisition
of T cell-recruiting and stimulating phenotypes.
The combination treatment of β-glucans and adoptive
transfer of TCR-engineered T cells is illustrated in Figure 3.
Along the lines of data put forward in Sections 2–4, we argue
that β-glucans, such as WGP and LEM facilitate the change of
an immune-tolerant tumor (Figure 3(a)) into one that is more
immune-responsive. This conversion may be governed by
increased numbers of antigen-presenting cells and an
enhanced inflammatory state, thereby sensitizing the tumor
for T cell entrance and activation (Figure 3(b)). Next, AT clearly
increases the number of tumor-specific T cells that, because of
the preceding β-glucan effects, are easily recruited into and
activated within the tumor, where they can take part in an
effective anti-tumor response (Figure 3(c)).
Preclinical studies with mice and clinical studies with
healthy subjects and cancer patients performed to date
clearly indicate that β-glucans potentiate innate immune
cells and enhance accumulation and activity of intratumoral
effector immune cells. Curdlan for example promotes the
differentiation of MDSCs into a more mature state, which
results in a reduced suppressive function [113]. In addition,
orally administered WGP modulates DCs, leading to expan-
sion and increased IFN-γ production of antigen-specific CD4+
and CD8+ T cells within tumors [108]. Skewing suppressive
immune populations into APCs with enhanced production of
type I IFNs and pro-inflammatory cytokines and chemo-
Figure 3. Beta-glucans support AT of solid tumors: proposed mechanisms of action. (a) Pre-treatment tumors harbor suppressive innate APCs like M2-TAMs, MDSCs and
N2-TANs that actively suppress recruitment into the tumor and local activation of effector lymphocytes, such as NK cells and CD8+ T cells. (b) Oral administration of β-
glucans results in tumors with increased numbers of immune-potentiating innate immune cells, as evidenced by their production of type I IFNs and inflammatory cytokines.
These APCs are derived from TDLN or nearby blood vessels, towardwhich theymigrated following exposure to β-glucans. Alternatively, these cells are converted from intra-
tumoral suppressive innate immune cells due to a heightened inflammatory state of the TME or β-glucans that have reached the tumor tissue. Consequently, also the
number and activation state of effector lymphocytes within the tumor increases. (c) Oral administration of β-glucans followed by AT results in an enhanced pool of
therapeutic T cells (harboring a TCR transgene that recognizes a tumor antigen) in the bloodstream. These therapeutic T cells are recruited into the tumor, which has
become sensitized by β-glucan treatment (as in panel B), and eradicate malignant cells. See text for more details. Abbreviations: APCs: antigen-presenting cells; AT: adoptive
T cell therapy; IL: interleukin; TDLN: tumor-draining lymph node, TNF-α: tumor necrosis factor alpha.
EXPERT OPINION ON BIOLOGICAL THERAPY 1035
attractants facilitates priming and differentiation of effector
lymphocytes, such as NK and Th1 cells, thereby augmenting
antitumor immune responses. Since tumors may escape
recognition by CD8+ T cells via deficiencies in antigen pro-
cessing and presentation, β-glucan-induced NK cell activity
(besides effects toward T cells themselves) may further sup-
port AT.
Future studies are required to reveal whether β-glucans are
transported to the TME and affect populations such as MDSCs,
TANs and TAMs directly, or whether they end up in tumor-
draining lymph nodes, where they trigger innate immune cells
and induce immune cells to migrate toward the tumor site.
Furthermore, it is worthwhile to assess whether immune-
potentiating effects of β-glucans are mediated by the micro-
biome; not trivial since it has recently been demonstrated that
distinct commensal bacterial species are related to clinical
response toward PD-1 checkpoint inhibitors [93].
It is noteworthy that clinical trials are mainly performed
with dietary insoluble particulate β-glucans derived from
yeast (S. cerevisiae) and fungi (L. edodus) that consist of a
β-(1→3) linked backbone with β-(1→6) linked side chains.
As reviewed by Stier and colleagues, β-glucans derived
from yeast and from fungi are known for their immune
modulating effects [61] (Tables 3–5), making these β-glu-
cans promising candidates to support AT. Also, in tumor
mouse models, both WGP and LEM cause delayed tumor
growth, which in some studies is accompanied by
enhanced conversion of non-responsive TILs toward Th1
responses as well as anti-tumor T cell activity. When com-
bining β-glucans with AT, this should be done in a manner
which maximizes the persistency of CD8+ TCR T cells. To
this end, when assessing the most optimal combination
schedule, T cell numbers should be monitored in blood
and tumor, and correlated with tumor growth as well as
the immune composition of tumor tissues. Most studies
observed stable tumor growth and ended their study
after a fixed number of weeks; yet it is recommended to
monitor immune parameters over longer time periods fol-
lowing administration of β-glucans.
One aspect that needs to be addressed to push the field
forward is a lack of clear uniformity with respect to the
annotation of these fibers as well as their source. In fact,
currently there exists a large variation in primary chemical
structures and molecular masses of β-glucans, which
mostly depends on differences in extraction and prepara-
tion procedures, making comparisons between studies
unnecessarily difficult. In addition, the relationship
between configurations and bioactivity of β-glucans
should be further studied to design or purify new β-glu-
cans with higher bioactivities.
In short, β-glucans have demonstrated ability and impact with
regards to reversion of immune suppressive innate cells to more
pro-inflammatory APCs. Beta-glucans can be considered as oral
adjuvants to AT, which is substantiated further due to ease of
implementation, high safety, low additional costs, and support of
self-assertiveness and self-awareness among cancer patients.
Thus, the use of orally applied food adjuvants, such as β-glucans,
would constitute a novel approach to rationally enhance endo-
genous immunity and support AT in treating cancer.
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